{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:57:31Z","timestamp":1761947851055},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/bf03261867","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T09:50:28Z","timestamp":1357293028000},"page":"331-342","source":"Crossref","is-referenced-by-count":11,"title":["Clopidogrel versus Aspirin in Patients with Atherothrombosis"],"prefix":"10.1007","volume":"10","author":[{"given":"Georgia","family":"Kourlaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Fragoulakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"issue":"Suppl 2","key":"1867_CR1","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/01.hjr.0000359235.59808.ba","volume":"16","author":"M. Rayner","year":"2009","unstructured":"Rayner M, Allender S, Scarborough P. Cardiovascular disease in Europe. Eur J Cardiovasc Prev Rehabil 2009; 16Suppl 2: S43\u20137","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"1867_CR2","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1161\/CIRCULATIONAHA.107.187998","volume":"117","author":"W. Rosamond","year":"2008","unstructured":"Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics \u2014 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25\u2013146","journal-title":"Circulation"},{"key":"1867_CR3","unstructured":"World Health Organization. Cardiovascular diseases (CVD). Fact sheet no. 317 [online]. Available from URL: www.who.int\/mediacentre\/factsheets\/fs317\/en\/print.html [Accessed 2010 Oct 8]"},{"key":"1867_CR4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1331\/154434504322904569","volume":"44","author":"M.A. Munger","year":"2004","unstructured":"Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (Wash) 2004; 44: S5\u201312","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"1867_CR5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/B:THRO.0000036029.56317.d1","volume":"17","author":"W.L. Duvall","year":"2004","unstructured":"Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004; 17: 51\u201361","journal-title":"J Thromb Thrombolysis"},{"key":"1867_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00043798-199412000-00009","volume":"1","author":"W.B. Kannel","year":"1994","unstructured":"Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1: 333\u20139","journal-title":"J Cardiovasc Risk"},{"key":"1867_CR7","unstructured":"Sanofi Aventis. Plavix\u00ae (clopidogrel bisulfate tablets): US prescribing information [online]. Available from URL: http:\/\/products.sanofi-aventis.us\/plavix\/plavix.html [Accessed 2010 Oct 8]"},{"key":"1867_CR8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"W.E. Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al., Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503\u201316","journal-title":"N Engl J Med"},{"key":"1867_CR9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"M.S. Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179\u201389","journal-title":"N Engl J Med"},{"key":"1867_CR10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S. Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494\u2013502","journal-title":"N Engl J Med"},{"key":"1867_CR11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329\u201339","journal-title":"Lancet"},{"key":"1867_CR12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"Z.M. Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607\u201321","journal-title":"Lancet"},{"key":"1867_CR13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","volume":"101","author":"C. Muller","year":"2000","unstructured":"Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101: 590\u20133","journal-title":"Circulation"},{"key":"1867_CR14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"M.E. Bertrand","year":"2000","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624\u20139","journal-title":"Circulation"},{"key":"1867_CR15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"S.R. Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527\u201333","journal-title":"Lancet"},{"key":"1867_CR16","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1161\/01.CIR.103.19.2332","volume":"103","author":"R. Waksman","year":"2001","unstructured":"Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001; 103: 2332\u20135","journal-title":"Circulation"},{"key":"1867_CR17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"M.S. Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224\u201332","journal-title":"JAMA"},{"key":"1867_CR18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.18553\/jmcp.2007.13.4.326","volume":"13","author":"J.W. Cheng","year":"2007","unstructured":"Cheng JW. Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. J Manag Care Pharm 2007; 13: 326\u201336","journal-title":"J Manag Care Pharm"},{"key":"1867_CR19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1524-4733.2009.00529.x","volume":"12","author":"J. Chen","year":"2009","unstructured":"Chen J, Bhatt DL, Dunn ES, et al. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. Value Health 2009; 12: 872\u20139","journal-title":"Value Health"},{"key":"1867_CR20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1185\/030079908X253762","volume":"24","author":"K. Berger","year":"2008","unstructured":"Berger K, Hessel F, Kreuzer J, et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin 2008; 24: 267\u201374","journal-title":"Curr Med Res Opin"},{"key":"1867_CR21","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1185\/03007990802222261","volume":"24","author":"J. Berg","year":"2008","unstructured":"Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin 2008; 24: 2089\u2013101","journal-title":"Curr Med Res Opin"},{"key":"1867_CR22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0828-282X(07)70870-X","volume":"23","author":"P. Kolm","year":"2007","unstructured":"Kolm P, Yuan Y, Veledar E, et al. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. Can J Cardiol 2007; 23: 1037\u201342","journal-title":"Can J Cardiol"},{"key":"1867_CR23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.clinthera.2007.06.020","volume":"29","author":"J. Berg","year":"2007","unstructured":"Berg J, Lindgren P, Spiesser J, et al. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther 2007; 29: 1184\u2013202","journal-title":"Clin Ther"},{"key":"1867_CR24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ahj.2005.02.044","volume":"151","author":"E.M. Mahoney","year":"2006","unstructured":"Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006; 151: 219\u201327","journal-title":"Am Heart J"},{"key":"1867_CR25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijcard.2005.06.026","volume":"109","author":"J. Karnon","year":"2006","unstructured":"Karnon J, Bakhai A, Brennan A, et al. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int J Cardiol 2006; 109: 307\u201316","journal-title":"Int J Cardiol"},{"key":"1867_CR26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjmed.2004.01.014","volume":"116","author":"M.D. Schleinitz","year":"2004","unstructured":"Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004; 116: 797\u2013806","journal-title":"Am J Med"},{"key":"1867_CR27","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJM200206063462309","volume":"346","author":"J.M. Gaspoz","year":"2002","unstructured":"Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800\u20136","journal-title":"N Engl J Med"},{"key":"1867_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1358836X9800300314","volume":"3","author":"M.A. Creager","year":"1998","unstructured":"Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998; 3: 257\u201360","journal-title":"Vasc Med"},{"key":"1867_CR29","unstructured":"Greek Ministry of Health. Drug price bulletin [online]. Available from URL: http:\/\/www.yyka.gov.gr\/ [Accessed 2012 Jan 11]"},{"key":"1867_CR30","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1524-4733.2008.00356.x","volume":"11","author":"N. Kontodimopoulos","year":"2008","unstructured":"Kontodimopoulos N, Pappa E, Niakas D, et al. Validity of the EuroQoL (EQ-5D) instrument in a Greek general population. Value Health 2008; 11:1162\u20139","journal-title":"Value Health"},{"key":"1867_CR31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/annonc\/mdp551","volume":"21","author":"N. Maniadakis","year":"2010","unstructured":"Maniadakis N, Fragoulakis V, Pallis AG, et al. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced\/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol 2010; 21: 1462\u20137","journal-title":"Ann Oncol"},{"key":"1867_CR32","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1185\/030079907X223765","volume":"23","author":"N. Maniadakis","year":"2007","unstructured":"Maniadakis N, Pallis A, Fragoulakis V, et al. Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin 2007; 23: 2251\u20137","journal-title":"Curr Med Res Opin"},{"key":"1867_CR33","unstructured":"Government Gazette. Presidential Decree 127\/2005. Increase of salaries of doctors\u2019 visits. 2005; Athens, Greece"},{"key":"1867_CR34","unstructured":"Government Gazette. Common Ministerial Decree Y4a\/OIK.1320\/1998. Definition of hospital charges. 1998; Athens, Greece"},{"key":"1867_CR35","unstructured":"Government Gazette. Presidential Decree 427\/1991, FEK 156. Costing of medical practices. 1991; Athens, Greece"},{"key":"1867_CR36","unstructured":"Government Gazette. Presidential Decree 157\/1991, FEK 62. Increase of salaries of doctors\u2019 visits and medical and dental practices. 1991; Athens, Greece"},{"key":"1867_CR37","volume-title":"Handbooks in health economic evaluation","author":"A. Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in health economic evaluation. New York: Oxford University Press Inc, 2006"},{"key":"1867_CR38","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","volume":"19","author":"J.A. Barber","year":"2000","unstructured":"Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 3219\u201336","journal-title":"Stat Med"},{"key":"1867_CR39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V","volume":"9","author":"M. Lothgren","year":"2000","unstructured":"Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623\u201330","journal-title":"Health Econ"},{"key":"1867_CR40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1524-4733.2004.71246.x","volume":"7","author":"T.O. Tengs","year":"2004","unstructured":"Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 2004; 7: 70\u20138","journal-title":"Value Health"},{"key":"1867_CR41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","volume":"13","author":"N. Devlin","year":"2004","unstructured":"Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437\u201352","journal-title":"Health Econ"},{"key":"1867_CR42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.0000028605.04359.FE","volume":"106","author":"R. Waksman","year":"2002","unstructured":"Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002; 106: 776\u20138","journal-title":"Circulation"},{"key":"1867_CR43","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"S.R. Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411\u201320","journal-title":"JAMA"},{"key":"1867_CR44","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000161383.06692.D4","volume":"111","author":"G. Patti","year":"2005","unstructured":"Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of peri-procedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099\u2013106","journal-title":"Circulation"},{"key":"1867_CR45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"H.G. Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518\u201328","journal-title":"Value Health"},{"issue":"Suppl. 4","key":"1867_CR46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00019053-200422004-00005","volume":"22","author":"I. Durand-Zaleski","year":"2004","unstructured":"Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004; 22 Suppl. 4: 19\u201327","journal-title":"Pharmacoeconomics"},{"key":"1867_CR47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3111\/200306055068","volume":"6","author":"L. Anneman","year":"2003","unstructured":"Anneman L, Lamotte M, Levy E, et al. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ 2003; 6: 55\u201368","journal-title":"J Med Econ"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03261867\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T07:24:40Z","timestamp":1644045880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03261867"}},"subtitle":["A CAPRIE-Based Cost-Effectiveness Model for Greece"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1007\/bf03261867","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}